Adrenoleukodystrophy Market - By Treatment: Corticosteroids, Gene Therapy, Bone Marrow Transplant, Others. By End-user: Hospitals, Specialty Clinics, Research Institutes. By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
The Global Adrenoleukodystrophy (ALD) market was valued at USD 489.9 million in 2023 and is projected to reach USD 1.29 billion by 2031, growing at a CAGR of 14.9%. ALD is a rare X-linked metabolic disorder affecting 1 in 17,000 newborns, causing progressive neurological deterioration and adrenal insufficiency. Increased newborn screening, gene therapy advancements, and orphan drug designations drive the market growth.
Key Market Drivers
Market Segmentation
By Treatment Type
By Disease Type
Regional Analysis
Competitive Landscape
Key Players:
Recent Developments
Need help?
Chat with our team in a minute.